Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,225 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00738699 | An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer(FAR-122) | terminated | Phase 2 | 415 | MorphotekINDUSTRY | 6 | Mar 30, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 |
| clinicaltrials |
| NCT01175733 | Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer(Vectibix) | completed | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | completed | Phase 2 | 9 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT01211275 | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma(N08CPA) | completed | Phase 1 / Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Feb 28, 2017 | clinicaltrials |
| NCT02583568 | Fluorescence Guided Surgery in Breast Cancer(MARGIN) | completed | Phase 1 / Phase 2 | 26 | University Medical Center GroningenOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT02519114 | Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma | unknown | Phase 1 / Phase 2 | 24 | Maastricht University Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00996567 | A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.(MesoMab) | completed | Phase 2 | 22 | University Hospital, GhentOTHER | 2 | Feb 9, 2017 | clinicaltrials |
| NCT01471782 | Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 93 | Amgen Research (Munich) GmbHINDUSTRY | 7 | Feb 8, 2017 | clinicaltrials |
| NCT01667536 | A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology | completed | Phase 2 | 105 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 8 | Feb 7, 2017 | clinicaltrials |
| NCT00423332 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | completed | Phase 2 | 105 | AstraZenecaINDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00080262 | Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) | completed | Phase 2 | 125 | R-PharmINDUSTRY | 10 | Jan 30, 2017 | clinicaltrials |
| NCT00358956 | A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer | completed | Phase 2 | 19 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Jan 30, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT01507103 | Tecemotide (L-BLP25) in Rectal Cancer(SPRINT) | completed | Phase 2 | 124 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jan 13, 2017 | clinicaltrials |
| NCT01374451 | Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET(COOPERATE-2) | terminated | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 19 | Dec 20, 2016 | clinicaltrials |
| NCT01549535 | Polyp Detection With The Peerscope System™ | completed | Phase 2 | 197 | PeerMedical Ltd.INDUSTRY | 3 | Nov 25, 2016 | clinicaltrials |
| NCT02465814 | Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids(ASTEROID 2) | completed | Phase 2 | 120 | BayerINDUSTRY | 16 | Nov 22, 2016 | clinicaltrials |
| NCT02208804 | Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization(SIM) | unknown | Phase 2 / Phase 3 | 25 | UMC UtrechtOTHER | 1 | Nov 9, 2016 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT01070927 | An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer | completed | Phase 2 | 7 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01508000 | Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases(BOS2) | terminated | Phase 2 | 44 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Oct 12, 2016 | clinicaltrials |
| NCT02478957 | Treatment of Indolent Systemic Mastocytosis With PA101 | completed | Phase 2 | 41 | Patara PharmaINDUSTRY | 5 | Sep 29, 2016 | clinicaltrials |
| NCT02828709 | Safety and Feasibility of IRE for SRMs | unknown | Phase 2 | 20 | Dr. Prof. M.P. Laguna PesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT01777776 | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | terminated | Phase 1 / Phase 2 | 28 | Array BioPharmaINDUSTRY | 4 | Sep 13, 2016 | clinicaltrials |
| NCT01286753 | A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation | completed | Phase 2 | 51 | Hoffmann-La RocheINDUSTRY | 4 | Sep 7, 2016 | clinicaltrials |
| NCT01826214 | Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia | completed | Phase 2 | 70 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 30, 2016 | clinicaltrials |
| NCT02621190 | Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs(CARVE) | withdrawn | Phase 2 | 0 | Erasmus Medical CenterOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02850783 | SLN in Colon Cancer Using a Multimodal Tracer | completed | Phase 2 / Phase 3 | 10 | VU University of AmsterdamOTHER | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01528345 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | terminated | Phase 2 | 97 | Novartis PharmaceuticalsINDUSTRY | 15 | Jul 11, 2016 | clinicaltrials |
| NCT01788566 | A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer | completed | Phase 2 | 61 | Eli Lilly and CompanyINDUSTRY | 7 | Jun 27, 2016 | clinicaltrials |
| NCT00327171 | Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | completed | Phase 2 | 218 | SanofiINDUSTRY | 11 | Jun 7, 2016 | clinicaltrials |
| NCT00259064 | Iressa v BSC (Best Supportive Care) in First Line NSCLC(INSTEP) | completed | Phase 2 / Phase 3 | 216 | AstraZenecaINDUSTRY | 5 | Jun 2, 2016 | clinicaltrials |
| NCT02029352 | Topical Green Tea Ointment in Treatment of Superficial Skin Cancer | completed | Phase 2 / Phase 3 | 42 | Maastricht University Medical CenterOTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT02285413 | Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients | completed | Phase 2 | 54 | Radboud University Medical CenterOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 8 | Apr 7, 2016 | clinicaltrials |
| NCT01403636 | A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | completed | Phase 2 | 167 | SanofiINDUSTRY | 6 | Mar 17, 2016 | clinicaltrials |
| NCT00936221 | Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients | completed | Phase 2 | 385 | AstraZenecaINDUSTRY | 12 | Mar 14, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT01124864 | A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. | completed | Phase 2 | 153 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 2, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL | withdrawn | Phase 2 / Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 17, 2016 | clinicaltrials |
| NCT00297258 | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | completed | Phase 2 | 148 | GlaxoSmithKlineINDUSTRY | 5 | Feb 3, 2016 | clinicaltrials |
| NCT00889590 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)(HR-GCT) | terminated | Phase 2 | 15 | Leiden University Medical CenterOTHER | 2 | Jan 26, 2016 | clinicaltrials |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer(PITCH) | completed | Phase 1 / Phase 2 | 21 | Leiden University Medical CenterOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials